Navigation Links
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Date:6/4/2009

NEWPORT, Ky., June 4 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Michael J. Valentino has been named to the position of President and Chief Executive Officer and continues as a member of the Company's Board of Directors. In addition to Mr. Valentino's announcement, Xanodyne completed an equity financing of $38 million led by MPM Capital. Current investors' participation also included; AIG Investments' sponsored funds, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures, LLC, and Union Springs.

Mr. Valentino most recently served as President and CEO, Adams Respiratory Therapeutics (Nasdaq: ARXT) and has over 30 years of experience in the healthcare industry, including a broad range of critical leadership positions at major pharmaceutical companies including Alpharma, Novartis AG, Pharmacia/Upjohn and Warner Lambert. Mr. Valentino successfully transformed Adams into a fully integrated specialty pharmaceutical company. In addition, under his leadership Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005. In January 2008, he successfully led the sale of the company to Reckitt Benckiser for $2.3B.

Mr. Valentino said, "I look forward to working closely with the Xanodyne management team to bring two exciting pipeline assets to the US marketplace within the next 12-18 months. Our efforts will be focused on aggressively executing our commercialization plans for Zipsor(TM) (diclofenac potassium - acute pain) and XP12B (tranexamic acid - heavy menstrual bleeding). The closing of our financing demonstrates the continued commitment of our investor group to complete the NDA process and execute the launch plans for these two important new products."

Rolf Classon, Chairman of the Board said, "The Board is excited about the achievement of these important milestones for Xanodyne. Mike brings major pharmaceutical and commercial experience to the team while the financing brings the critical resources needed for the launches. Xanodyne is now in a position to expand its current commercial product portfolio with an emerging pipeline to generate near term growth."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
2. US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. CorVel Announces Revenues and Earnings
5. Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program
6. Orlando Dermatology Aesthetic & Clinical (ODAC) Conference Announces Its 2010 Event
7. Synthetech Announces Fiscal 2009 Results
8. Martek Announces Second Quarter 2009 Financial Results
9. Medi-Share Program Announces New Healthcare Program Offerings for Christian Community
10. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
11. One Woman Initiative Announces First Grants to Womens Organizations in Five Nations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: